Wall Street Journal · Xavier Martinez ·

Pharmaceutical leaders are skeptical of claims that AI could cure most diseases within a decade; the US FDA has yet to clear any AI-designed biotech drugs

No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle

In this story FDA

Pharmaceutical leaders are skeptical of claims that AI could cure most diseases within a decade; the US FDA has yet to clear any AI-designed biotech drugs

Lead Source

Wall Street Journal — Pharmaceutical leaders are skeptical of claims that AI could cure most diseases within a decade; the US FDA has yet to clear any AI-designed biotech drugs ↗

How this story grew

Coverage · 0 Discussion · 0

4:31 AM10:31 AM UTC

Related stories

Financial Times: Clinicians raise concerns over medical AI adoption beyond diagnostics and imaging, citing limited clinical and performance data on its broader effectiveness

Ghosts of Electricity: A look at why the oft-discussed predictions that AI will deliver double-digit GDP growth in advanced economies are extremely unlikely over the next 10-15 years

New York Times: Insilico, which uses AI to accelerate drug discovery, says early data shows rentosertib, a drug whose structure was generated with AI's help, could slow aging

Axios: Lawmakers and Hill staffers in both parties say AI leaders are becoming a political liability as they swing between claims of prosperity and existential dangers

Reuters: Mistral and other European AI startups accuse US rivals of using safety concerns to entrench their dominance, rejecting Anthropic's calls to pace the frontier

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif